ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
Essex enriches and complements Emmes’ services
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Subscribe To Our Newsletter & Stay Updated
